Trial Profile
Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/ Undifferentiated Thyroid Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 08 Feb 2022 Status changed from recruiting to completed.
- 31 Jan 2020 Status changed from active, no longer recruiting to recruiting.
- 06 Jan 2020 Planned End Date changed from 1 Oct 2019 to 1 Oct 2021.